Previous 10 | Next 10 |
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q1 2021 Earnings Call May 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q1 2021 Earnings Call Tra...
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2021 Earnings Conference Call May 4, 2021, 5:00 PM ET Company Participants Joshua Higa - Director, Investor Relations Emil Kakkis - President and CEO Camille Bedrosian - Chief Medical Officer Erik Harris - Chief Commercial Officer Mardi Dier - Chief Fi...
Ultragenyx Pharmaceutical (RARE): Q1 GAAP EPS of -$2.03 misses by $0.79.Revenue of $99.39M (+173.7% Y/Y) beats by $21.51M.Press Release For further details see: Ultragenyx Pharmaceutical EPS misses by $0.79, beats on revenue
First quarter 2021 total revenue of $99.4 million and Crysvita 1 revenue to Ultragenyx of $42.1 million 2021 Crysvita revenue in Ultragenyx territories 1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with appr...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed through a rotation out of growt...
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., ...
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4...
NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing da...
Ultragenyx Pharmaceutical (RARE) successfully completes an End-of-Phase 2 (EOP2) meeting with the FDA for the DTX301 ornithine transcarbamylase ((OTC)) deficiency gene therapy program. Based on the outcome of this meeting, Ultragenyx has finalized the Phase 3 study design, which will include ...
NOVATO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced the successful completion of an End-of-Phase 2 ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...